Gilead, Dragonfly ink pact to develop natural killer cell engagers in oncology, inflammation Ruchika Sharma5 May 2022 9:15 AM ISTUnder the terms of the agreement, Gilead will make a $300 million upfront payment to Dragonfly.
Stop sale of counterfeit HIV drugs: J&J files plea against drug distributors, pharmacies Roshni Dhar29 April 2022 6:30 PM ISTJohnson & Johnson has filed a lawsuit against drug distributors and a pharmacy seeking to stop the sale of counterfeit versions of its HIV drugs,...
Health Bulletin 29/April/2022 Roshni Dhar29 April 2022 5:07 PM ISTHere are the top health stories for today:NMC officials facing CBI probe on allegations of giving approvals to medical colleges for cash: ReportThe...
Stop sale of counterfeit HIV drugs: JnJ files plea against drug distributors, pharmacies Ruchika Sharma28 April 2022 4:24 PM ISTJnJ said counterfeit bottles sometimes contained a different HIV drug than what was on the label, and in one case contained the powerful antipsychotic...
Gilead Sciences Remdesivir gets USFDA nod for young children Ruchika Sharma26 April 2022 3:06 PM ISTUnder the expanded indication, a three-day Remdesivir treatment regimen is recommended to help prevent hospitalization in non-hospitalized COVID-19...
Kite gets USFDA nod for new CAR T-cell therapy site in Maryland Ruchika Sharma20 April 2022 1:12 PM ISTSanta Monica: Kite, a Gilead Company has announced the U.S. Food and Drug Administration (USFDA) has approved commercial production at the company's...
Lupin gets USFDA nod for generic equivalent of Vemlidy Tablets Ruchika Sharma18 April 2022 2:32 PM ISTThis product will be manufactured at Lupin's Nagpur facility in India.
USFDA lifts partial clinical hold on studies evaluating magrolimab in combination with azacitidine: Gilead Sciences Ruchika Sharma12 April 2022 4:49 PM ISTFoster City: Gilead Sciences, Inc. has recently announced that the U.S. Food and Drug Administration (USFDA) has lifted the partial clinical hold...
GSK to get USD 1.25 billion from Gilead Sciences to settle dispute of HIV based drug unit Ruchika Sharma3 Feb 2022 2:44 PM ISTGilead will also pay a 3 percent royalty until 2027 on sales of Biktarvy and on future US sales of any product containing its main component.
Gilead Sciences Remdesivir gets USFDA nod to treat non-hospitalized COVID patients Ruchika Sharma25 Jan 2022 1:48 PM ISTFoster City: Gilead Sciences, Inc. has recently announced that the U.S. Food and Drug Administration (USFDA) has granted expedited approval of a...
Gilead Sciences withdraws use of Zydelig for 2 types of cancer Ruchika Sharma16 Jan 2022 11:00 AM ISTNew Delhi: Gilead Sciences Inc on Friday notified the U.S. health regulator of its decision to voluntarily withdraw the use of its drug Zydelig...
Gilead Sciences, Merck collaborate to evaluate Trodelvy in combo with Keytruda Ruchika Sharma31 Oct 2021 9:30 AM ISTFoster City: Gilead Sciences, Inc. has recently announced the company has entered into a clinical trial collaboration and supply agreement with Merck...
